Table 3.
Variables | HR (95%CI) | P-value |
---|---|---|
Univariate analyses | ||
Age (years) (>60 vs ≤60) | 2.015 (1.460–2.781) | <0.001 |
Gender (female vs male) | 1.228 (0.171–8.794) | 0.838 |
T stage (T3 and T4 vs T1 and T2) | 1.760 (1.223–2.535) | 0.002 |
N stage (N2 and N3 vs N0 and N1) | 2.299 (1.571–3.359) | <0.001 |
M stage (M1 vs M0) | 4.859 (2.900–8.139) | <0.001 |
AJCC tumor stage (III and IV vs I and II) | 1.624 (1.373–1.921) | <0.001 |
AKR1C1 (high group vs low group) | 0.640 (0.440–0.931) | 0.020 |
Multivariate analyses | ||
Age (years) (>60 vs ≤60) | 2.276 (1.613–3.212) | <0.001 |
T stage (T3 and T4 vs T1 and T2) | 0.985 (0.581–1.668) | 0.954 |
N stage (N2 and N3 vs N0 and N1) | 1.075 (0.591–1.955) | 0.812 |
AJCC tumor stage (III and IV vs I and II) | 1.654 (1.195–2.290) | 0.002 |
AKR1C1 (high group vs low group) | 0.652 (0.440–0.964) | 0.032 |
Abbreviations: HR, hazard ratio; CI, confidence interval; OS, overall survival; AJCC, American Joint Committee on Cancer.